e-Drug3D 1524 |
cas 274693-27-5 |
CLASS BLOOD |
ROUTE (list) ORAL |
ATC code |
PK parameters F 36 PERCENT Solubility AQUEOUS SOLUBILITY OF APPROXIMATELY 10 MICROGRAM / MILLILITER AT ROOM TEMPERATURE |
Target TARGET P2Y12 ADP-RECEPTOR PDB Ligand code = TIQ (link to the list of PDB complexes) Download experimental 3D coordinates of TIQ with added hydrogens |
DrugCentral P2Y purinoceptor 12 UNIPROT Q9H244 P2RY12 |
Download SDF file | (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2hydroxyethoxy)cyclopentane-1,2-diol Formula: Calculated chemical properties: MW 522.58 NB_atoms 36 XLogP 2.01 PSA 132.065 NB_HD 4 NB_HA 10 fsp3 0.57 Lipinski(0=no;1=yes) 0 |
FDA NDA 022433 (label) INN (TICAGRELOR) BRILINTA (ASTRAZENECA) APPROVAL= AP YEAR= 2011 NDA 208390 (pdf not found) INN (TICAGRELOR) TICAGRELOR (WATSON LABS INC) APPROVAL= AP YEAR= 2018 NDA 208531 (pdf not found) INN (TICAGRELOR) TICAGRELOR (AMNEAL) APPROVAL= AP YEAR= 2019 DISCONTINUED NDA 208575 (pdf not found) INN (TICAGRELOR) TICAGRELOR (HISUN PHARM HANGZHOU) APPROVAL= AP YEAR= 2019 NDA 208508 (pdf not found) INN (TICAGRELOR) TICAGRELOR (SUNSHINE) APPROVAL= AP YEAR= 2020 NDA 208596 (pdf not found) INN (TICAGRELOR) TICAGRELOR (MSN) APPROVAL= AP YEAR= 2020 NDA 208597 (pdf not found) INN (TICAGRELOR) TICAGRELOR (MYLAN) APPROVAL= AP YEAR= 2021 NDA 208567 (pdf not found) INN (TICAGRELOR) TICAGRELOR (ALKEM LABS LTD) APPROVAL= AP YEAR= 2023 NDA 208599 (pdf not found) INN (TICAGRELOR) TICAGRELOR (PRINSTON INC) APPROVAL= AP YEAR= 2024 NDA 208541 (pdf not found) INN (TICAGRELOR) TICAGRELOR (DR REDDYS) APPROVAL= AP YEAR= 2024 NDA 208537 (pdf not found) INN (TICAGRELOR) TICAGRELOR (INVAGEN PHARMS) APPROVAL= AP YEAR= 2025 NDA 208576 (pdf not found) INN (TICAGRELOR) TICAGRELOR (ALEMBIC) APPROVAL= AP YEAR= 2025 NDA 208584 (pdf not found) INN (TICAGRELOR) TICAGRELOR (APOTEX) APPROVAL= AP YEAR= 2025 NDA 218962 (pdf not found) INN (TICAGRELOR) TICAGRELOR (SCIEGEN PHARMS) APPROVAL= AP YEAR= 2025 NDA 210219 (pdf not found) INN (TICAGRELOR) TICAGRELOR (ALKEM LABS LTD) APPROVAL= AP YEAR= 2025 NDA 211498 (pdf not found) INN (TICAGRELOR) TICAGRELOR (TARO) APPROVAL= AP YEAR= 2025 NDA 212258 (pdf not found) INN (TICAGRELOR) TICAGRELOR (MACLEODS PHARMS LTD) APPROVAL= AP YEAR= 2025 NDA 216187 (pdf not found) INN (TICAGRELOR) TICAGRELOR (CHANGZHOU PHARM) APPROVAL= AP YEAR= 2025 NDA 208539 (pdf not found) INN (TICAGRELOR) TICAGRELOR (MICRO LABS) APPROVAL= AP YEAR= 2026 NDA 217679 (pdf not found) INN (TICAGRELOR) TICAGRELOR (MANKIND PHARMA) APPROVAL= AP YEAR= 2026 NDA 219006 (pdf not found) INN (TICAGRELOR) TICAGRELOR (ZHEJIANG JINGXIN) APPROVAL= AP YEAR= 2026 |
Other links: | |
e-Drug3D 863 |
cas 220347-05-7 |
CLASS BLOOD |
ROUTE (list) - |
ATC code |
PK parameters F 36 PERCENT |
Target TARGET P2Y12 ADP-RECEPTOR |
DrugCentral P2Y purinoceptor 12 UNIPROT Q9H244 P2RY12 |
Download SDF file | 1,2,3-Cyclopentanetriol, 4-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-, (1S,2R,3S,4R)- Formula: Calculated chemical properties: MW 478.53 NB_atoms 33 XLogP 2.00 PSA 122.17 NB_HD 4 NB_HA 9 fsp3 0.52 Lipinski(0=no;1=yes) 1 |
FDA - |
Other links: |